

November 22, 1999. Pursuant to 37 C.F.R. § 1.17, a check in the amount of \$1170.00 is enclosed, which includes the process fee (\$870.00) for a three-month extension of time. If the check is inadvertently omitted, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Assistant Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/10012461/01973.

AMENDMENTS

In the Claims:

Please cancel claim 21 and amend the remaining claims as follows:

1. (Amended) A method of reducing the growth rate of a [cell] tumor, comprising contacting [said] a cell within said tumor with (a) a gene encoding a functional p53 protein and (b) a DNA damaging agent in a combined amount effective to [kill] inhibit the growth of said [cell] tumor.
-
22. (Amended) The method of claim [21] 1, wherein said tumor cell is a malignant cell.
26. (Amended) The method of claim [21] 1, wherein said tumor cell is located within an animal at a tumor site.
46. (Amended) The method of claim [21] 1, wherein the tumor cell is contacted with a DNA damaging agent by irradiating the tumor cell with X-ray radiation, UV-irradiation, γ -irradiation or microwaves.

SUB F⁹ 51. (Amended) The method claim [21] 1, wherein the tumor cell is contacted with a pharmaceutical composition comprising a DNA damaging compound.

SUB F¹¹ 83. (Amended) The method of claim 26, wherein said gene is delivered to said tumor endoscopically, intravenously, intratracheally, intralesionally, percutaneously or subcutaneously.

SUB F¹² 90. (Amended) The method of claim 12, wherein the period between administration of the [vector] gene and DNA damaging agent is between 6 and 12 hours.

91. (Amended) The method of claim 12, wherein the period between administration of the [vector] gene and DNA damaging agent is about 12 hours.

D¹ 96. ⁶⁶ (Amended) The method of claim [21] 1, wherein said tumor cell is an epithelial tumor cell.